Effect of a New Beta-Blocker, Nipradilol, on Cardiac Function and Neurohumoral Factors in Idiopathic Dilated Cardiomyopathy

概要

論文の詳細を見る
This study investigated the therapeutic efficacy of a new beta-blocker, hipradilol, a non-selective agent with vasodilating activity, for the treatment of idiopathic dilated cardiomyopathy(DCM). The New York Heart Association functional class improved in the nipradilol group(n=9, p<0.01), but not in the control group who received conventional therapy(n=9). The observation period was 19±7 months in the nipradilol group, and 20±9 months in the control group. Before therapy there was no difference in heart rate between the 2 groups(76±12 vs 79±15 beats/min). The end-diastolic and end-systolic left ventricular dimensions decreased in the nipradilol group(p<0.05), but not in the control group. Radionuclide ventriculography revealed that the left ventricular ejection fraction increased in the nipradilol group(27±8 to 41±18%, p<0.05), but not in the control group(27±11 to 27±8%). Plasma norepinephrine tended to be lowered, although not significantly, whereas plasma alphaatrial natriuretic peptide significantly decreased after the therapy(p<0.01)in the treatment group. Lymphocyte beta-adrenoceptors were up-regulated in the nipradilol group(p<0.05). None of these parameters changed during the observation period in the control group. Thus, nipradilol improved symptoms and cardiac function with a favorable effect on neurohumoral factors in patients with DCM.
社団法人日本循環器学会の論文
1996-04-20